

Daniel Scotcher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1985549/publications.pdf>

Version: 2024-02-01

21
papers

413
citations

759233

12
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

416
citing authors

#	ARTICLE	IF	CITATIONS
1	PBPK Simulation-Based Evaluation of Ganciclovir Crystalluria Risk Factors: Effect of Renal Impairment, Old Age, and Low Fluid Intake. <i>AAPS Journal</i> , 2022, 24, 13.	4.4	5
2	Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically-Based Pharmacokinetic Modeling and Dose Adjustment. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 643-652.	4.7	12
3	Coproporphyrin I as an Endogenous Biomarker to Detect Reduced <i>OATP1B</i> Activity and Shift in Elimination Route in Chronic Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 615-626.	4.7	9
4	Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1187-1199.	3.5	20
5	Hepatic Scaling Factors for In Vitro-In Vivo Extrapolation of Metabolic Drug Clearance in Patients with Colorectal Cancer with Liver Metastasis. <i>Drug Metabolism and Disposition</i> , 2021, 49, 563-571.	3.3	9
6	Bringing Microphysiological Systems to Practical Use: Evaluation of transporter-mediated DDI and Renal Clearance. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
7	Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats. <i>Molecular Pharmaceutics</i> , 2021, 18, 2997-3009.	4.6	10
8	Quantitative Proteomic Map of Enzymes and Transporters in the Human Kidney: Stepping Closer to Mechanistic Kidney Models to Define Local Kinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1389-1400.	4.7	14
9	Physiologically-Based Pharmacokinetic Modelling of Creatinine-Drug Interactions in the Chronic Kidney Disease Population. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 695-706.	2.5	15
10	Mass spectrometry-based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin. <i>FEBS Letters</i> , 2020, 594, 4134-4150.	2.8	21
11	Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine-Drug Interactions. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 282-293.	2.5	20
12	A Novel Physiologically-Based Model of Creatinine Renal Disposition to Integrate Current Knowledge of Systems Parameters and Clinical Observations. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 310-321.	2.5	14
13	Scaling Factors for Clearance in Adult Liver Cirrhosis. <i>Drug Metabolism and Disposition</i> , 2020, 48, 1271-1282.	3.3	16
14	Quantitative Translation of Microfluidic Transporter <i>in Vitro</i> Data to <i>in Vivo</i> Reveals Impaired Albumin-Facilitated Indoxyl Sulfate Secretion in Chronic Kidney Disease. <i>Molecular Pharmaceutics</i> , 2019, 16, 4551-4562.	4.6	30
15	Towards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal Clearance. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 157-168.	2.5	17
16	Noninvasive Preclinical and Clinical Imaging of Liver Transporter Function Relevant to Drug-Induced Liver Injury. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 627-651.	0.2	5
17	Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance. <i>Drug Metabolism and Disposition</i> , 2017, 45, 556-568.	3.3	29
18	Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 360, 484-495.	2.5	56

#	ARTICLE	IF	CITATIONS
19	Key to Opening Kidney for In Vitro–In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data. AAPS Journal, 2016, 18, 1067-1081.	4.4	38
20	Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance. European Journal of Pharmaceutical Sciences, 2016, 94, 59-71.	4.0	44
21	Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation. AAPS Journal, 2016, 18, 1082-1094.	4.4	29